As a novel adjunctive medication for the treatment of Parkinson's disease, Ongentys (opicapone) has been widely used in clinical practice in recent years.

How Effective is Ongentys (Opicapone) in Treatment?

Improving Fluctuations in Motor Symptoms

By inhibiting the activity of the COMT enzyme, opicapone reduces the metabolism of levodopa, thereby prolonging the duration of its effect.

Clinical studies have shown that this medication can effectively reduce the duration of "off" periods, increase the duration of "on" periods in patients with Parkinson's disease, and improve fluctuations in motor symptoms.

Enhancing Quality of Life

By stabilizing the plasma concentration of levodopa, opicapone helps patients achieve more sustained symptom control and reduces fluctuations in motor symptoms, thereby improving patients' ability to perform daily activities and their overall quality of life.

Long-Term Treatment Benefits

The once-daily administration regimen of opicapone is simple and easy to follow, resulting in high patient compliance, making it suitable for long-term use.

Suitable Population for Ongentys (Opicapone)

Main Indications

Ongentys is indicated for patients with Parkinson's disease who are receiving levodopa/carbidopa treatment but experience "off" episodes.

Such patients typically exhibit fluctuations in drug efficacy, manifested as obvious "on-off" phenomena.

Precautions for Special Populations

Patients with hepatic impairment: Dose adjustment is required for patients with moderate hepatic impairment, while patients with severe hepatic impairment should avoid using this medication.

Patients with renal impairment: No dose adjustment is needed for patients with mild to moderate renal impairment, but patients with end-stage renal disease should avoid using it.

Elderly patients: No dose adjustment is required, but close monitoring for adverse reactions is necessary.

Pregnant and lactating women: Based on animal data suggesting potential harm to the fetus, a careful assessment of the risk-benefit ratio should be conducted.

Contraindicated Populations

Patients concurrently using non-selective monoamine oxidase inhibitors (MAOIs).

Patients with a history of pheochromocytoma, paraganglioma, or other catecholamine-secreting tumors.

Medication Monitoring for Ongentys (Opicapone)

Routine Monitoring Items

Cardiovascular function: Regularly monitor changes in heart rate and blood pressure.

Psychiatric symptoms: Observe for the occurrence of hallucinations or psychotic symptoms.

Motor symptoms: Assess whether dyskinesia has worsened.

Weight changes: Measure body weight regularly.

Adverse Reaction Monitoring

Cardiovascular effects: Arrhythmias, increased heart rate, and excessive changes in blood pressure may occur.

Daytime somnolence: Evaluate the patient's alertness during daily activities.

Hypotension/syncope: Monitor for symptoms of orthostatic hypotension.

Dyskinesia: Observe for the worsening of existing dyskinesia or the development of new dyskinesia.

Impulse control disorders: Inquire about increased impulsive behaviors such as gambling or shopping.

Psychiatric symptoms: Be alert to the occurrence of psychiatric symptoms such as hallucinations and delusions.